NOXXON PHARMA NV (ALNOX.PA) Stock Price & Overview
EPA:ALNOX • NL0012044762
Current stock price
The current stock price of ALNOX.PA is 0.041 EUR. Today ALNOX.PA is down by -18%. In the past month the price decreased by -38.99%. In the past year, price decreased by -88.28%.
ALNOX.PA Key Statistics
- Market Cap
- 3.055M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.22
- Dividend Yield
- N/A
ALNOX.PA Stock Performance
ALNOX.PA Stock Chart
ALNOX.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALNOX.PA. When comparing the yearly performance of all stocks, ALNOX.PA is a bad performer in the overall market: 99.33% of all stocks are doing better.
ALNOX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALNOX.PA. ALNOX.PA may be in some trouble as it scores bad on both profitability and health.
ALNOX.PA Earnings
ALNOX.PA Forecast & Estimates
10 analysts have analysed ALNOX.PA and the average price target is 7.39 EUR. This implies a price increase of 17919.93% is expected in the next year compared to the current price of 0.041.
ALNOX.PA Groups
Sector & Classification
ALNOX.PA Financial Highlights
Over the last trailing twelve months ALNOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 40.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.9% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALNOX.PA Ownership
ALNOX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.81 | 41.518B | ||
| ARGX | ARGENX SE | 29.04 | 41.431B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.62B | ||
| 2X1 | ABIVAX SA | N/A | 7.62B | ||
| ABVX | ABIVAX SA | N/A | 7.612B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| GLPG | GALAPAGOS NV | N/A | 1.605B | ||
| NANO | NANOBIOTIX | N/A | 1.361B | ||
| PHGN | PHARMING GROUP NV | 47.2 | 1.009B | ||
| PHARM | PHARMING GROUP NV | 47.3 | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 946.39M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M | ||
| IVA | INVENTIVA SA | N/A | 907.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALNOX.PA
Company Profile
NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
Company Info
IPO: 2018-09-10
NOXXON PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 13
Phone: 49307262470.0
NOXXON PHARMA NV / ALNOX.PA FAQ
Can you describe the business of NOXXON PHARMA NV?
NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
What is the current price of ALNOX stock?
The current stock price of ALNOX.PA is 0.041 EUR. The price decreased by -18% in the last trading session.
Does ALNOX stock pay dividends?
ALNOX.PA does not pay a dividend.
How is the ChartMill rating for NOXXON PHARMA NV?
ALNOX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting ALNOX stock to perform?
10 analysts have analysed ALNOX.PA and the average price target is 7.39 EUR. This implies a price increase of 17919.93% is expected in the next year compared to the current price of 0.041.
What is the GICS sector and industry of ALNOX stock?
NOXXON PHARMA NV (ALNOX.PA) operates in the Health Care sector and the Biotechnology industry.